Results 41 to 50 of about 5,633 (190)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience

, 2017
Over the years, allopurinol has been widely used as the preferred choice of urate lowering therapy in patients with gout. However, its role in patients with renal impairment is limited; and adverse reactions are well documented.
Nor Shuhaila Shahril, Narisa Sulaiman, Anna Misyail Abdul Rashid, Mohamad Syafeeq Faeez Md Noh, Ahmad Zaidi Othman   +4 more
core   +2 more sources

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients

Renal Failure, 2019
The aim of this study was to evaluate the efficacy and tolerability of febuxostat in renal transplant recipients who were previously treated with allopurinol (the daily oral dose is 100 mg).
Yanchun Li, Min Liu, Xuelei Zhang, Yuewu Lu, Juan Meng   +4 more
doaj   +1 more source

Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers.

PLoS ONE, 2016
UnlabelledThe present study aimed to investigate the pharmacokinetic properties of febuxostat in healthy Chinese male volunteers and evaluate whether the two formulations of febuxostat 40-mg and 80-mg tablets are bioequivalent.
Zhu Luo, Feng Nan, Jia Miao, Zhihui Chen, Mei Li, Maozhi Liang   +5 more
doaj   +1 more source

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study

Scientific Reports, 2022
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown.
Hiroshi Kataoka, Toshio Mochizuki, Mamiko Ohara, Yuki Tsuruta, Naomi Iwasa, Rie Yoshida, Ken Tsuchiya, Kosaku Nitta, Kenjiro Kimura, Tatsuo Hosoya, the FEATHER Investigators   +10 more
doaj   +1 more source

Febuxostat‐induced acute liver injury

, 2016
Febuxostat is a unique xanthine oxidase inhibitor that was approved for the prevention of gout in the United States in 2009. Unlike allopurinol, febuxostat is not a nucleoside analogue and has a higher specificity for xanthine oxidase. Although this drug
Matt Bohm, Bohm, Matt, Vuppalanchi, Raj, Chalasani, Naga, Naga Chalasani, Raj Vuppalanchi   +5 more
core   +1 more source

A New Regimen for Induction of Metabolic Syndrome and the Effect of Febuxostat in Ovariectomized Female Albino Rats

SVU - International Journal of Medical Sciences, 2021
Background: Metabolic syndrome (MetS) is increasing worldwide and correlates with serum uric acid and high fat combined with highfructose diet (HFFD). Fat raises triglycerides. Fructose increases uric acid. We hypothesized that HFFD in menopause may have
Rana Toghan, Rehab H. Abdel-Aziz*, Tahany Abbas, Khaled A. Abdel-Sater   +3 more
doaj   +1 more source

Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cells.

PLoS ONE
Uric acid induces radical oxygen species formation, endothelial inflammation, and endothelial dysfunction which contributes to the progression of atherosclerosis.
Karel H van der Pol, Jan Koenderink, Jeroen J M W van den Heuvel, Petra van den Broek, Janny Peters, Imke D W van Bunningen, Jeanne Pertijs, Frans G M Russel, Jim Koldenhof, Wim J Morshuis, Joris van Drongelen, Tom J J Schirris, Andries van der Meer, Gerard A Rongen   +13 more
doaj   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis

Arthritis &Rheumatology, EarlyView.
Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source

Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat. [PDF]

Biopharm Drug Dispos
Ikemura K., Kobayashi S., Wang D., et al. Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat.
Ikemura K, Kobayashi S, Wang D, Okuda M.
europepmc   +2 more sources

The clinical pharmacokinetics and pharmacodynamics of febuxostat

, 2018
Febuxostat lowers serum urate (SU) by inhibiting xanthine oxidoreductase. The data on the effect of renal function on the pharmacokinetics (PK) of febuxostat and the response of SU pharmacodynamics; PD) to febuxostat are limited and discordant ...
Kamel, Bishoy
core   +1 more source